Nektar Therapeutics
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-96.7M | $-153.5M | $-81.2M | $-53.9M | $-162.0M | $-171.9M | $-134.0M | $-37.9M |
| Depreciation & Amortization | $12.6M | $13.2M | $11.4M | $12.9M | $14.3M | $14.5M | $15.0M | $16.6M |
| Depreciation | — | $13.2M | $11.4M | $11.7M | $13.0M | $13.8M | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | $17.0M | $17.7M | $16.2M | $18.9M | $17.4M |
| Net Cash from Operating Activities | $-80.4M | $-117.0M | $-73.1M | $-142.0M | $-38.5M | $-129.8M | $-113.7M | $-55.9M |
| Investing Activities | ||||||||
| Capital Expenditures | $9.7M | $6.4M | $11.2M | $10.0M | $4.1M | $10.6M | $9.7M | $31.5M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-28.8M | $-82.4M | — | — | $49.9M | $113.0M | $-112.0M | $16.7M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $54.4M | $203.6M | — | — | $2.2M | $26.8M | $222.3M | $7.5M |
| Net Change in Cash | $-54.9M | $4.1M | $43.2M | $-26.7M | $13.6M | $10.1M | $-2.4M | $-31.8M |
| Free Cash Flow | $-90.1M | $-123.4M | $-84.3M | $-152.0M | $-42.6M | $-140.3M | $-123.5M | $-87.3M |